Skip to main content
. Author manuscript; available in PMC: 2018 Jun 15.
Published in final edited form as: Cancer. 2017 Feb 17;123(12):2360–2367. doi: 10.1002/cncr.30591

Figure 3.

Figure 3

AFP Decline After 2 Cycles of VI Therapy Shown are the changes in AFP derived as [(initial measurement-final measurement)/initial measurement] plotted on a log-scale. The red line represents a 90% decline in alphafetoprotein between patient enrollment and the end of the 2 cycles of VI therapy. Ninety percent decline represents an alphafetoprotein response as defined in the protocol.